America's Blood Centers
Powered by Community.

NEWSLETTER

A weekly chronicle of events and issues impacting the blood community

2026 Issue #19 June 23, 2026

INSIDE:

WORD IN WASHINGTON 2
BRIEFLY NOTED.....3
PEOPLE.....4
INFECTIOUS DISEASES UPDATE.....5
ADRP Trends in Donor Relations Study Results Are Available 6
MEMBER NEWS.....6
ADVANCED THERAPIES NEWS 7
GLOBAL NEWS 8
COMPANY NEWS 8
CALENDAR.....10
POSITIONS.....10

Effectiveness of Bacterial Screening of Platelets Studied

Authors of a paper published in *Vox Sanguinis*, "aim[ed] to evaluate the effectiveness and limitations of bacterial screening of platelet donations in England from 2014-2023." Specifically, the study analyzed, "the number and types of bacteria detected over time in apheresis and pooled platelet donations and compared those with the number of reported near-misses and bacterial transfusion-transmitted infections (TTIs). [The researchers also] analy[z]ed the time from collection to detection of different bacterial species and used that data to discuss the effectiveness and limitations of the current bacterial screening strategy." Over the 10-year period, the study included, "a total of 2,745,220 platelet components, comprising 1,249,513 (45.4 percent) pooled and 1,495,707 (54.5 percent) apheresis platelet donations, were collected and subjected to bacterial screening by England's national blood service. From these, 5,833 (0.21 percent) donations were initially reactive in a bacterial culture bottle. A higher number of initial reactives were observed for pooled platelets than for apheresis platelets donations (3,232, 0.25 percent from 1,249,513 vs. 2,601, 0.17 percent from 1,495,707, respectively). Of these, 1,451 donations were confirmed positive for bacterial contamination with over four-fold higher percentages observed in pooled platelets than apheresis donations (0.09 percent [1,096/1,249,513] vs. 0.02 percent [362/1,495,707], $p < 0.0001$), respectively."

The researchers found that the, "number of confirmed bacterial contaminations of pooled platelet donations increased by 58 percent over the study period from 419 (from 586,947 screened) in 2014–2018 to 663 (from 662,566 screened) in 2019–2023, whereas the number of bacterially contaminated apheresis donations declined by 27 percent from 213 (from 848,104 screened) in 2014–2018 to 156 (from 647,603 screened) in 2019–2023. [Additionally, there] was a similar increase in platelet units with indeterminate contamination in both pooled and apheresis donations from 305 in 2014–2018 to 619 in 2018–2023 for pooled platelets and from 269 to 305 for apheresis donations." The authors noted that, "[a]lthough this coincided with a gradual increase in the number of pooled platelet donations manufactured in England (from 76,094 in 2014 to 147,630 in 2023), the rate of confirmed and indeterminate bacterial contamination in pooled platelets increased from 2014–2018 to 2019–2023 (0.52–0.93 per 1,000 and 0.71–1.00 per 1,000 donations, respectively, Chi-square test for both changes, $p < 0.0001$). In contrast, the frequency of confirmed and indeterminate bacterial contamination in apheresis platelets has remained relatively unchanged."

The study concluded that, "[d]uring this 10-year study period, bacterial screening of 2,745,220 platelet components identified 2,949 donations with bacterial contamination, and only one confirmed bacterial TTI was reported. Despite this, platelet donations collected in England demonstrated a substantial increase in the rate of

(continued on page 2)

Effectiveness of Bacterial Screening of Platelets Studied (continued from page 1)

bacterial contaminations, although the detected bacteria were mostly considered clinically non-significant. It will be important to identify how these contaminations occurred and could be prevented. Our findings also clearly demonstrate a limitation of bacterial screening: namely bacterial growth often becomes detectable only after the platelet donation had potentially been supplied for clinical use. Whether the extended large-volume delayed sampling or the molecular screening utilizing 16S rRNA PCR without compromising the sensitivity of screening could address this limitation remains to be seen."

Citation: Chugh, V., Secret, S., Davison, K., *et al*. "Bacterial screening of platelet donations in England, 2014–2023." *Vox Sanguinis*. 2026.

WORD IN WASHINGTON

***Bloomberg* is reporting that, "U.S. lawmakers are pressing the Pentagon to speed up the mass production and deployment of synthetic blood critical for traumatic injuries on the battlefield as Congress seeks to shore up the U.S. biotechnology field."** The article explained that, "Congress and the Pentagon are investing in the emerging biotechnology field as a critical driver of national security. The National Security Commission on Emerging Biotechnology has called on the U.S. government to spend at least $15 billion over the next five years to unlock private capital and investment in the sector." The news agency also noted that, "[t]he Defense Advanced Research Projects Agency (DARPA) is funding the development of deployable, [a] shelf-stable whole blood substitute to treat hemorrhages. DARPA has backed research into synthetic products designed to replicate key functions of whole blood, including oxygen delivery, hemostatic support, and restoration of circulating volume. [The agency] said its goal is to have [a U.S.] Food and Drug Administration-authorized, deployable technology as early as fiscal year 2029."

(Source: *Bloomberg*, "Pentagon Urged to Mass-Produce Synthetic Blood for War Injuries," 6/22/26)

The Administration for Strategic Preparedness and Response (ASPR), part of the U.S. Department of Health and Human Services (HHS), has announced the DS-MRN Challenge: Digital Stockpile & Manufacturing Response Network. This is initiative is being led by ASPR's Center for Industrial Base Management and Supply Chain (IBMSC) and will, "award up to $2.04 million for innovative solutions that strengthen the nation's ability to rapidly produce and distribute critical medical products during public health emergencies and supply chain disruptions. The challenge invites innovators from industry, academia, nonprofit organizations, and government to develop concepts for a future Digital Stockpile & Manufacturing Response Network. Through a three-phase competition, participants will design and validate approaches that strengthen domestic medical manufacturing, supply chain coordination, and emergency

(continued on page 3)

The *ABC Newsletter* (ISSN #1092-0412) is published by America's Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2026 by America's Blood Centers. Reproduction of the *ABC Newsletter* is forbidden unless permission is granted by the publisher (ABC members need not obtain prior permission if proper credit is given).
ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognizes the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the health care system; promote partnerships, policies, and programs that increase awareness about the need for blood donation; and serve as a thought leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

America's Blood Centers
Chief Executive Officer: Kate Fry
Editor: Mack Benton
Subscriptions Director: Leslie Maundy
Annual Subscription Rate: $420

Send subscription queries to
memberservices@americasblood.org
America's Blood Centers
1717 K St. NW, Suite 900, Washington, DC 20006
Phone: (202) 393-5725
Send news tips to newsletter@americasblood.org.

WORD IN WASHINGTON (continued from page 2)

response capabilities. [The competition] includes three phases: Concept Development; Innovation Development; and Live Validation. Up to eight finalists will receive $5,000 prizes in Phase I and advance to an in-person pitch event in Washington, D.C. Up to three pitch event winners will receive $150,000 each. Phase II winning teams will refine and mature their concepts through two development milestones, with up to $150,000 in additional milestone prizes available per team. Finalists advancing to the Live Validation phase will test their solutions in real-world simulations and compete for a share of up to $1.1 million. In total, ASPR may award up to $2.04 million in prizes. ASPR will host a series of DS-MRN Challenge Prize virtual information sessions beginning in July 2026. To register for the events or to learn more about the competition, visit the prize challenge website."

(Source: ASPR Announcement, 6/16/26)

BRIEFLY NOTED

The Prehospital Blood Transfusion Coalition (PBTC) recently announced that, "[t]here are now over 400 9-1-1 ground emergency medical services (EMS) nationwide that carry blood products to the scene of life-threatening bleeding." The coalition also noted in the announcement that, "[PBTC] is helping to develop a proposal for EMS agencies to be reimbursed for blood transfusions by the Centers for Medicare & Medicaid Services (CMS), as well as working on prehospital blood policy recommendations for Congress and state decision-makers. Coalition members are actively working to educate EMS personnel, blood suppliers, healthcare communities, hospitals, and policymakers about the problem of preventable hemorrhage deaths, and the available solution of prehospital transfusion. [In April 2026, [PBTC] co-hosted the inaugural Economics of Prehospital Blood Conference in Washington, D.C. to bring together organi[z]ations and decision-makers to accelerate progress."

(Source: PBTC Announcement, 6/23/26)

PBTC and PWW Advisory Group (PWW|AG) have shared the results of a national "flash poll" that aimed to, "better understand the economic realities of implementing and sustaining prehospital blood administration programs." An executive summary in the report explained that 55 EMS agencies responded to poll. Reported findings include:

- "the [a]verage annual program expenses range from approximately $36,000 to $77,000 depending on provider type, with total reported annual costs nearing $2 million across respondents;
- the total expense per patient is substantial, averaging nearly $12,000 and exceeding $28,000 in some fire-based systems; and
- reimbursements mechanisms remain limited. Even when optimized, per patient reimbursement increases are modest (approximately 12 percent for ground ambulance) and fall far short of covering the 2,000 percent increased cost per patient. As a result, prehospital blood programs currently operate with a significant funding gap, raising important questions about long-term financial sustainability."

(Source: PBTC and PWW|AG Prehospital Blood Administration Programs Flash Poll Results, 6/17/26)

The American Medical Association (AMA) House of Delegates recently approved a resolution to address the clinical laboratory workforce shortage and sustainability. Specifically, the AMA recognized, "the unique and critical role of medical laboratory professionals in patient care and public health and the urgent need to address workforce shortages; and [noted that the association will support] advocacy efforts to sustain and strengthen clinical laboratory training and education programs, including assistance for faculty development and infrastructure, to address capacity and recruitment needs; and [the AMA will]

(continued on page 4)

BRIEFLY NOTED (continued from page 3)

collaborate with relevant stakeholders, including accrediting bodies, educational institutions, healthcare organizations, and professional societies, to promote awareness of clinical laboratory careers, as members of the physician-led healthcare team, among students and the public." The resolution was introduced by the American Society for Clinical Pathology (ASCP), the American Society of Cytopathology, the American Society of Dermatopathology, the College of American Pathologists, and the National Association of Medical Examiners."

(Source: AMA Resolution, 6/10/26)

PEOPLE



LifeShare Blood Center has announced that **Katrina Billingsley, MSTM, MLS(ASCP), SBBCM** is retiring as director of Scientific Services. She joined the organization in 1999, "after earning her Medical Technology degree from Louisiana State University. Returning to the organization in 2008 as senior research technologist in the newly established Scientific Services Laboratory, she rose steadily through the ranks—advancing to supervisor in 2011, manager in 2017, and director in 2019. Under her leadership, the Scientific Services Laboratory expanded from a single technologist into a thriving team of diverse talent, education, and laboratory experience; significantly enhancing the organization's laboratory capabilities and rare donor recruitment efforts. During this time, Ms. Billingsley earned her Specialist in Blood Banking (SBB) certification in 2011 and her Master of Science in Transfusion Medicine (MSTM) in 2017, reflecting her unwavering commitment to professional excellence. In 2016, Ms. Billingsley founded LifeShare's SBB Program, shaping the professional development of the next generation of blood bank specialists. "Katrina's contributions to LifeShare and to the broader blood banking community have been immeasurable said Dr. Chad A. Douglas, president and chief executive officer of LifeShare Blood Center in the announcement. "Her vision, leadership, and dedication will leave an enduring legacy that will continue to benefit patients, donors, and professionals for years to come."




Tricia Sanders, MBA, LSSGB, MLS(ASCP)CM, SBBCM has been named director of Education Services at LifeShare. A blood center announcement noted that, "[i]n this role, Ms. Sanders will oversee LifeShare's Specialist in Blood Banking program, phlebotomy school, and employee training and development programs across the organization. Ms. Sanders [has] more than 20 years of experience in transfusion medicine and laboratory education, with a career spanning hospital laboratories, blood centers, immunohematology reference laboratories, and healthcare education settings. Her areas of expertise include technical leadership, complex serology, operational improvement, regulatory compliance, and professional development. [She is] especially committed to mentoring the next generation of laboratory professionals and advancing the field through innovative, practical education." Jessica Sears, executive director of Operational Effectiveness at LifeShare stated in the announcement, "[w]e are thrilled to have Tricia join the LifeShare [f]amily. Her depth of knowledge and passion for education make her ideally positioned to expand our educational programs and we are excited to see how our programs evolve under her strategic direction."

(Source: LifeShare Blood Center Announcement, 6/19/26)

(continued on page 5)

PEOPLE (continued from page 4)



Sarah "Kate" Hartman, MD has been named chief scientific officer at Gulf Coast Blood. According to a blood center announcement, "[s]he joins Gulf Coast Blood from Baylor College of Medicine and Ben Taub Hospital, where she has provided leadership in transfusion medicine, apheresis services, coagulation laboratories, and large-scale quality and safety initiatives. Her professional accomplishments include:

- [a]dvancing scientific discovery and promoting evidence-based practice;
- [d]esigning and supporting patient blood management (PBM) programs that improve patient outcomes;
- [m]odernizing laboratory operations and integrating next-generation clinical technology;
- [c]ollaborating across disciplines to enhance safety, quality, and operational efficiency;
- [t]eaching, mentoring, and developing future clinical leaders; [and]
- [p]ublishing research in leading medical journals, including *Annals of Internal Medicine* and *Transfusion*, *The American Journal of Emergency Medicine*, and other respected peer-reviewed journals, as well as book chapters with the Association for the Advancement of Blood & Biotherapies, the American Society for Clinical Pathology, and the College of American Pathologists."

(Source: Gulf Coast Blood Announcement, 6/17/26)

INFECTIOUS DISEASES UPDATE

EBOLA

On June 19th, the World Health Organization (WHO) updated the status of the Ebola disease outbreak in the Democratic Republic of the Congo (DRC). As of June 17th, "a [total] of 896 confirmed cases, including 232 deaths, have been reported from the DRC. As of June 18th, Uganda has reported 19 confirmed cases including two deaths, as well as one probable case. In Uganda, the outbreak remains epidemiologically linked to transmission originating in the DRC, with evidence of both imported infections and secondary transmission among contacts and healthcare workers. Uganda has not reported any new cases since June 5th." Last month, the WHO declared the Ebola disease outbreak in the DRC and Uganda caused by Bundibugyo virus a, "public health emergency of international concern (PHEIC), but [noted that it] does not meet the criteria of pandemic emergency, as defined in the International Health Regulations (2005) (IHR)." The U.S. Centers for Disease Control and Prevention (CDC) published an update on June 23rd update stating that the U.S. "is responding to an outbreak of Ebola disease in remote areas of the (DRC and Uganda.) To date, no cases of Ebola disease have been confirmed in the United States because of this outbreak. The overall risk to the American public and travelers remains low." On May 18th, the CDC announced that it had, "enhanced travel screening, entry restrictions, and public health measures to prevent Ebola virus disease from entering the United States amid ongoing outbreaks in East and Central Africa." The CDC has not classified the affected region as having "widespread transmission of Ebola virus," which would trigger donor interventions in the U.S. The U.S. Food and Drug Administration (FDA) guidance requires that, "in the event that one or more countries is classified by CDC as having widespread transmission of Ebola virus, your donor history questionnaire (DHQ), including your full-length and abbreviated DHQ, and accompanying materials, must incorporate elements to assess prospective donors for symptoms of recent or current illness with Ebola virus infection or disease, and travel to, or residence in, an area endemic for Ebola virus in accordance with 21 CFR 630.10(e)(2)."

(Source: WHO Update, 6/19/26; CDC Update, 6/23/26)


INSIDE ABC

The programs and services described in the Inside ABC section are available to ABC member blood centers and their staffs only, unless otherwise specified.

ADRP Trends in Donor Relations Study Results Are Available

Participants can now access the results of the *ADRP Trends in Donor Relations Study*. This survey is a strategic tool for blood centers to use in evaluating the performance of collection and recruitment operations and marketing strategies in comparison to your domestic and international colleagues. A key feature of the reporting platform is the ability to view how your operations compare to others using a variety of dynamic filters, including blood center location, collection levels, and employee count. Only centers that participated in the survey will have access to this information. Blood centers that did not participate can purchase the survey report for $599. Please contact us with any questions.

MEMBER NEWS



Our Blood Institute (OBI) has launched CytoGrowth Solutions. The company will develop, "specialized blood-and cell-based products used to support the growing cell therapy industry, particularly therapies designed to help patients fight cancer and other serious diseases using their own immune systems," according to an article from the Oklahoma Department of Commerce. The company will also use, "methods developed through OBI's research and development work [as it] converts previously underused blood components into nutrient products that can support cell growth for therapeutic development." John Armitage, MD, president and chief executive officer (CEO) of OBI, explained in the article, "[w]e're taking salvage products, things that were being thrown out before, and turning them into lifesaving contributions and cures." Charles Mooney, vice president of BioDevelopment at OBI added in the article, "[p]eople rely on things like expired platelets and male AB serum, which is 2 percent of the population, as the primary thing that helps their reengineered cells grow. There's not enough of that in the world to support one blockbuster drug, much less dozens of drugs." CytoGrowth has opened, "a dedicated Oklahoma City facility that will manufacture four products designed to support cell and gene therapy development."

(Source: Oklahoma Department of Commerce, "From Donated Blood to Biotech: CytoGrowth Solutions Launches in OKC," 5/15/26)

The Blood Connection recently partnered with Beast Philanthropy, the charitable organization founded by Jimmy Donaldson (also known as MrBeast), "[to] challenge the Greenville community to donate blood and help save up to 1,000 lives in one day." A blood center news release noted that The Blood Connection hosted a June 23rd blood drive at the Greenville Convention Center, "inspired by the wish of a 19-year-old patient fighting leukemia [to hold the most epic blood drive the city has ever seen in honor] of the hundreds of thousands of children around the world battling blood cancers. Delisa English, MBA, president and CEO of The Blood Connection, stated in the news release, "MrBeast demonstrates the impact that can come from

(continued on page 7)

MEMBER NEWS (continued from page 6)

a good heart and a little bit of bravery. Every day we fight to deliver a constant, daily supply of blood for patients in need while only 3 percent of eligible donors across the United States give blood. With the amazing support of Jimmy and the MrBeast community, we can make a wish come true for countless children in North Carolina who desperately need a blood transfusion."

(Source: The Blood Connection News Release, 6/17/26)

ADVANCED THERAPIES NEWS

The Blood & Cells Advocacy Roster (BCAR) recently announced that *PharmaPhorum* has published an article titled "Stem the Bleeding: Rising to Meet the Growing Demand for CGT Starting Material." The authors of the article are Adrienne Mendoza, MHA, chief operating officer at BBG Advanced Therapies, Kate Fry, MBA, CAE, chief executive officer of America's Blood Centers (ABC), Joy Duemke, MBA, a global executive at Terumo Blood and Cell Technologies, and Brianna Schoen, PhD, vice president of Scientific Development at Vitalant. The article discusses the barriers preventing accessibility to starting material for advanced therapies and explores, "donor recruitment, starting material supply chains, and how blood centers and existing blood infrastructure can address the need." ABC joined BCAR last year.

(Source: *PharmaPhorum*, "Stem the Bleeding: Rising to Meet the Growing Demand for CGT Starting Material," 6/15/26)

CorrectSequence Therapeutics has announced that the, "first sickle cell disease (SCD) patient being treated in China with its [investigational] high-precision base-editing therapy CS-206 has remained free of vaso-occlusive crises (VOCs) for more than 15 months following engraftment." A company news release also noted that, "starting from 60 Days after the last red-cell transfusion, the patient has remained free from VOCs and anemia for 13 consecutive months, achieving the primary efficacy endpoint. The follow-up data demonstrated favorable safety and efficacy of CS-206. The patient, a 21-year-old woman from Nigeria, had experienced recurrent severe VOCs prior to treatment with CS-206. After receiving CS-206 treatment in February 2025, the patient achieved rapid and efficient hematopoietic reconstitution, with neutrophil engraftment observed on Day 13 and platelet counts exceeding 50×10^9/L on Day 21 post-treatment. Within one month after treatment, fetal hemoglobin (HbF) levels increased significantly and continuously, while sickle hemoglobin (HbS) levels declined substantially and persistently. Beginning at [m]onth three after treatment, the HbF-to-HbS ratio stabilized at approximately 6:4 and has remained stable thereafter. No product-related adverse events have been observed to date. This [investigational] therapy effectively suppresses red blood cell sickling and significantly reduces vaso-occlusive crises and hemolysis. Compared with CRISPR-based gene-editing therapies for SCD, CS-206 offers the technological advantage of precise single-base correction without introducing DNA double-strand breaks, thereby avoiding risks such as large genomic deletions, chromosomal abnormalities, and off-target mutations."

(Source: CorrectSequence Therapeutics News Release, 6/2/26)

Sign up for ABC's &ADRP's *Pulse of Leadership*



GLOBAL NEWS

Canadian Blood Services has announced a, "regulatory submission to Health Canada to introduce a new malaria nucleic acid test (NAT) into its blood donor screening process." The announcement also noted that, "[i]f approved, malaria NAT will remove certain longstanding barriers to blood donation for individuals who have previously had—and fully recovered from—a malaria infection. This approach will also shorten or eliminate donation waiting periods for those who have recently lived in regions where malaria is common. Current screening relies heavily on donor eligibility questions and waiting periods, as there was no test available in Canada sensitive enough to detect low levels of malaria parasites in donated blood. Unfortunately, this has prevented many healthy individuals from donating." Canadian Blood Services added in the announcement that, "[we are] committed to maintaining a safe, sufficient national blood and plasma supply while expanding donor participation and inclusion. This includes regularly reviewing eligibility criteria based on the latest scientific evidence, as well as advancements in technology and testing."

(Source: Canadian Blood Services Announcement, 6/17/26)

The Ministry of Health in Spain recently reported that, "during the past year, a total of 1,070,169 people made blood and plasma donations in Spain, which allowed for 1,662,035 blood and blood component donations. These figures represent a decrease of 2.78 percent in the number of donors and almost one percent in the volume of donations compared to the data recorded in 2024. [Additionally, from] the donations made last year, 478,229 liters of plasma were obtained, which represents an increase of 1.32 percent compared to the previous year. [Of the total collected,] 67,551 liters came from plasmapheresis [of which] 108,304 procedures were carried out in 2025."

(Source: *Demócrata*, "More than 1.07 million people donated blood and plasma in Spain in 2025, 2.8 percent less than the previous year," 6/14/26)

COMPANY NEWS

Velico Medical, Inc. has released findings from a phase I first-in-human clinical trial examining Frontline On Demand Plasma (ODP). A company news release explained that key findings from the study include:

- "[a]ll 24 participants successfully completed the trial;
- [i]nfusions were well tolerated across all cohorts;
- [n]o thromboembolic events were observed;
- [t]reatment-emergent adverse events occurred at similar frequencies between FrontlineODP and frozen plasma;
- [m]inor coagulation changes observed were not clinically significant; [and]
- [p]rotein preservation within the FrontlineODP™ spray dried plasma manufacturing system was successfully demonstrated."

Additional information from the study has been published in *Transfusion*. Frontline ODP is, "a next-generation spray-dried plasma product designed to transform access to lifesaving plasma transfusion in emergency, military, prehospital and austere care environments."

(Source: Velico Medical, Inc. News Release, 6/18/26)

(continued on page 9)

COMPANY NEWS (continued from page 8)

Blood Bank Computer Systems, Inc. (BBSC) recently announced that Shepeard Community Blood Center has implemented the company's ForLife Biologics Platform® with the BBCS BECS (blood establishment computer system) 6.6. According to a news release, the platform is an, "end-to-end solution that streamlines donor management, collections, manufacturing, testing, distribution, compliance, and reporting workflows within a single unified system." Shepeard Community Blood Center Chief Executive Officer Benjamin Prijatel, MBA added in the news release, "[w]e are thrilled to officially launch the ForLife Biologics Platform®. This implementation represents an important investment in the future of our organization and our ability to serve donors, hospitals, and patients across our communities. BBCS has been an exceptional partner throughout this journey."


(Source: BBCS News Release, 6/9/26)

The Association for the Advancement of Blood & Biotherapies (AABB) has announced that, "University Hospital in Newark, N.J. has become the first organization to achieve AABB accreditation for Emergency Prehospital and Scheduled Out-of-Hospital Transfusions." According to a news release, "[t]his accreditation—a new offering from AABB—helps to ensure that patients who undergo blood transfusions outside of hospitals receive the same high-quality level of care that they would receive at a hospital. Organizations who achieve this accreditation have demonstrated their commitment to safety and quality by adhering to AABB's Standards for Emergency Prehospital and Scheduled Out-of-Hospital Transfusions, which were developed by experts and establish requirements for blood storage, transport and administration in out-of-hospital settings, as well as documentation, traceability, personnel qualifications and quality system oversight."

(Source: AABB Announcement, 6/19/26)

Moderna, Inc. has announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted, "[unanimously] that the benefits of mRNA-1010, Moderna's investigational seasonal influenza vaccine, outweigh its risks for the prevention of influenza disease in adults 50 through 64 years of age and voted [unanimously that] the benefits of mRNA-1010 outweigh its risks for the prevention of influenza disease in adults 65 years of age and older." A news release explained that the, "safety profile of mRNA-1010 observed in the phase III program was consistent with previously reported studies of Moderna's influenza vaccine candidate. The FDA will consider the recommendations of VRBPAC as part of its ongoing review of Moderna's Biologics License Application (BLA) for mRNA-1010. [The investigational vaccine] has been accepted for regulatory review in the United States, European Union, Canada, and Australia. Moderna has received an FDA Prescription Drug User Fee Act (PDUFA) goal date of August 5th, 2026. Regulatory submissions in additional countries are planned during 2026."

(Source: Moderna, Inc. News Release, 6/18/26)



CALENDAR

Note to subscribers: *Submissions for a free listing in this calendar (published weekly) are welcome. Send information to newsletter@americasblood.org. (For a more detailed announcement in the weekly "Meetings" section of the newsletter, please include program information.)*

2026

June 25-26. **National Heart, Lung, and Blood Institute (NHLBI) and the Sickle Cell Disease Association of America, Inc. (SCDAA) "Research That Heals: Partnering with Patients to Transform SCD Care." Rockville, Md. (Hybrid).** More information is coming soon.

Sept. 16-17. **ADRP: The Association for Blood Donor Professionals Master Class (Virtual).** Registration is open. More information is available here.

Oct. 4-7. **Association for Advancing Tissue and Biologics (AATB) Annual Meeting. San Francisco, Calf.** More information available here.

Oct. 5-7. **ARM Cell & Gene Meeting on the Mesa. Phoenix, Ariz.** More information is available here.

Oct. 14-15. **Biomedical Excellence for Safer Transfusion (BEST) Collaborative Member Meeting. Atlanta, Ga.** More information is available here.

Oct. 17-19. **Association for the Advancement of Blood & Biotherapies (AABB) Annual Meeting. Atlanta, Ga.** More information is coming soon.

Nov. 5-6. **2026 ABC Women's Executive Leadership Community *Rise &* Lead Workshop. San Antonio, Texas.** More information is coming soon.

Nov. 17-20. **American Society for Clinical Pathology (ASCP) and Canadian Association of Pathologists- Association Canadienne des Pathologistes (CAP-ACP) Joint Annual Meeting. Montreal, QC.** Registration is open. More information available here.

2027

March 8-11. **2027 ABC Annual Meeting. Atlanta, Ga.** More information is coming soon.

May 11-13. **2027 ADRP: The Association for Blood Donor Professionals Annual Conference Columbus, Ohio.** More information is coming soon.

CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC members. There are charges for non-members: $139 per placement for *ABC Newsletter* subscribers and $279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: newsletter@americasblood.org

POSITIONS

Director of Supply Chain (Piedmont, SC). The Blood Connection seeks an experienced and strategic Director of Supply Chain to lead procurement, inventory management, warehousing, logistics, and distribution operations across its growing multi-state blood center network. Reporting to the Vice President of Operational Support Services, this leader will oversee the supply chain infrastructure that supports donor centers, mobile collection operations, laboratories, manufacturing facilities, warehouses, and distribution activities. Responsibilities include directing inventory planning and replenishment, managing vendor relationships and contract negotiations, overseeing warehouse and distribution operations, implementing advanced ERP and supply chain technologies, and driving process improvements that enhance efficiency, compliance, and service levels. The Director will collaborate closely with Finance, Quality, and Operations

(continued on page 11)

POSITIONS (continued from page 10)

leadership on budgeting, strategic planning, and operational excellence initiatives while developing and mentoring a high-performing supply chain team. The role requires a bachelor's degree in Supply Chain Management, Logistics, or a related field, along with 7–10 years of progressive leadership experience in healthcare, blood banking, pharmaceuticals, or another regulated environment. Candidates should possess strong analytical, project management, and change leadership skills, as well as a proven track record of optimizing complex supply chain operations. This is an exceptional opportunity to lead a mission-critical function that directly supports lifesaving services throughout the communities we serve. Apply today: https://jobs.dayforcehcm.com/en-US/tbc/CANDIDATEPORTAL/jobs/17735

Transfusion Lab Manager Needed! Join Florida's leading blood center, **OneBlood**, as a Blood Bank Lab Manager in Bay Pines, FL. Bring your leadership, technical expertise, and management experience to support the transfusion testing procedures on patient and/or donor samples. Qualified candidates should possess five (5) or more years' experience in a related field. A valid and current Florida Clinical Laboratory Supervisor license in Immunohematology required; SBB certification preferred. To apply and view a complete Job Description of this Lab Manager position, visit www.oneblood.org/careers. OneBlood, Inc. is an Equal Opportunity Employer/Vet/Disability.

Regional Director (Tallahassee, FL). OneBlood is seeking an experienced Regional Director to oversee donor blood collection operations and lead regional teams in support of its lifesaving mission in the Panhandle. This leadership role is responsible for driving operational excellence, ensuring compliance with regulatory and accreditation standards, and achieving donor recruitment and collection goals across the region. Candidates should possess strong leadership, analytical, communication, and team management skills, along with the ability to build collaborative relationships and improve operational performance. A bachelor's degree and significant management experience in healthcare, blood banking, or a related field are preferred. Travel within the region may be required. This position is based in Tallahassee, Florida, and offers the opportunity to join a mission-based organization dedicated to maintaining a safe and reliable blood supply for local communities. Competitive compensation and a comprehensive benefits package offered. Apply at **OneBlood Careers**.

Executive Director (Spokane, WA). Vitalant is seeking an exceptional, mission-driven leader to serve as the Executive Director for our Spokane region. This influential role oversees daily operations, community engagement, mobile and fixed-site collections performance, and ensures alignment with organizational strategy and standards. The Executive Director partners closely with regional and enterprise leadership to drive collection success, strengthen customer and donor relationships, and foster a culture grounded in accountability, learning, and collaboration. We're Looking for a Leader Who Can: Translate strategy into effective local execution. Inspire and develop high-performing teams. Build strong partnerships across community and stakeholder groups. Drive operational excellence, adaptability, and innovation. This role offers a competitive compensation and total rewards package, including a performance-based bonus plan that recognizes the significance and impact of this position. Interested applicants can apply at //www.vitalant.org/careers.

Medical Laboratory Scientist. LifeSouth Community Blood Centers is looking for experienced Medical Laboratory Scientists, with a passion for making a difference. Current openings: Gainesville, Florida (Multiple shifts available; rotating weekends and holidays), Jacksonville, FL (Overnight), and Atlanta, Georgia (Morning shift; rotating weekends and holidays). **Legal authorization to work in the United States is required. We do not provide visa sponsorship for these positions.** Shift differential applies to eligible evening and overnight hours; sign-on and/or relocation bonuses may also be offered to qualified candidates. Our Medical Laboratory Scientists work in a full-service, accredited immunohematology laboratory following established policies and procedures to resolve complex immunohematology and compatibility problems to provide the safest donor blood for patients in our community. Join us in our mission to make sure blood is available when it's needed most. Visit our careers page to learn more about this position and apply today!

Laboratory Supervisor (Evenings). LifeSouth Community Blood Centers is looking for an experienced Laboratory Supervisor with a passion for making a difference to lead our evening shift Immunohematology Reference Laboratory team, in **Gainesville, FL**. Shift differential applies to eligible evening and overnight hours; sign-on and relocation bonuses may also be offered to qualified candidates. In this role, you'll oversee daily operations, ensure adherence to established policies and procedures, and support staff in resolving complex testing and compatibility challenges. You'll play a critical part in identifying and addressing issues that may impact test performance or result reporting, while mentoring and guiding team members to uphold the highest standards of quality and safety. Your leadership will help ensure the delivery of the safest donor blood for patients in our community. We are committed to excellence in customer service and patient care. Join us in our mission to make sure blood is available when it's needed most. Visit our careers page to learn more about this position and apply today!

(continued on page 12)

POSITIONS (continued from page 11)

Purchasing Manager. LifeSouth Community Blood Centers is seeking a highly skilled leader with proven management experience and a passion for making a difference. The **Purchasing Manager** at our headquarters location in **Gainesville, FL** is responsible for vendor selection, negotiation, establishment and maintenance of all purchased materials, supplies, equipment, and services used by the company. The Purchasing Manager is organized and decisive and can motivate the team to reach daily and long-range goals. Join our team and help us continue our dedication to making sure the blood is there when you or your family is in need. Visit our careers page to learn more about this position, and apply here!